Xoma Neuprex License Lifts Stock As Investors Return To Small-Cap Biotech
Executive Summary
Xoma returned to favor on Wall Street with a $35 mil. licensing deal for Neuprex (rBPI-21), giving Baxter worldwide rights to the bactericidal/permeability-increasing protein product for meningococcemia and all future antibacterial and anti-endotoxin indications.
You may also be interested in...
Ilex Finds Comfortable Niche As Wall Street Attitude Towards CROs Sours
Ilex Oncology's combination of contract research and a proprietary pipeline is finding favor on Wall Street as the CRO industry overall weathers a slump.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials